David D. Kim

Cooley advised the underwriters in Merus’ $172.5 million follow-on offering. Jefferies, BofA Securities, Guggenheim Securities and William Blair acted as joint book-running managers for the offering. Merus is a clinical-stage oncology company developing innovative, full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics. Partners Denny Won, Courtney Thorne and Div Gupta led the Cooley team.

Cooley advised the underwriters in the upsized initial public offering of Sagimet Biosciences, a clinical-stage biotechnology company, at $85 million.

Cooley advised Acelyrin, INC., a late-stage biopharmaceutical company, in its $621 million initial public offering, the second-largest biotechnology IPO and largest clinical-stage biotechnology IPO ever.

Cooley advised the underwriters on PROCEPT BioRobotics’ $188.5 million initial public offering of 7,539,400 shares of common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. BofA Securities, Inc. and Goldman Sachs & Co. LLC acted as joint lead book-running managers for the offering. PROCEPT BioRobotics, whose securities now trade on the Nasdaq Global Market under the symbol “PRCT,” is a commercial-stage surgical robotics company focused on advancing patient care by developing transformative solutions in urology. Partners Charlie Kim, Kristin VanderPas and Dave Peinsipp led the Cooley team.

Cooley advised the underwriters on Erasca’s $345 million initial public offering of 21,562,500 shares of common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. J.P. Morgan, Morgan Stanley, BofA Securities, Evercore ISI and Guggenheim Securities acted as joint book-running managers for the offering. Erasca, whose securities now trade on the Nasdaq Global Select Market under the symbol ERAS, is a clinical-stage precision oncology company focused on discovering, developing and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Partners Charlie Kim, Sean Clayton and Kristin VanderPas led the Cooley team.